Department of Microbiology and Medicinal Chemistry, Wroclaw University of Technology, Wyspiańskiego Str. 27, 50-370 Wroclaw, Poland.
Research and Development Center NOVASOME, Olsztyńska Str. 5, 51-423 Wrocław, Poland.
Biomed Pharmacother. 2016 Oct;83:771-775. doi: 10.1016/j.biopha.2016.07.014. Epub 2016 Jul 30.
Azelaic acid is a naturally occurring saturated C9-dicarboxylic acid which has been shown to be effective in the treatment of comedonal acne and inflammatory acne, as well as hiperpigmentary skin disorders. The aim of the present study is to compare new developed liposomal hydrogel (lipogel) and commercially available product in terms of the active substance-azelaic acid bioavailability. Topical formulations were evaluated for physical parameters, such as pH measurement, organoleptic evaluation and liposome size analysis in lipogel formulation. In addition, studies were performed on in vitro antimicrobial preservation, stability and accumulation in the stratum corneum according to guidelines established by European Pharmacopoeia and International Conferences on Harmonisation. The new formula for liposomal gel with azelaic acid has the stability required for pharmaceutical preparations. Moreover, presented formulation F2 reveals a very high accumulation (187.5μg/cm) of an active substance in the stratum corneum, which results in opportunity to decrease of the API content to 10% in comparison to a reference formula: commercially available cream with 20% of azelaic acid. The study reveals that the final formula of lipogel F2 with azelaic acid had acceptable physical parameters that showed that they were compatible with the skin and in addition this formulation passed stability studies. In vitro antimicrobial preservation studies showed that the formulated lipogel F2 showed strong antibacterial activity; thus, no preservatives were added to the final composition of the preparation. The present study concludes that the formulated lipogel F2 with azelaic acid is stable, efficient in antimicrobial preservation and reveals improved active substance bioavailability.
壬二酸是一种天然存在的饱和 C9 二羧酸,已被证明在治疗粉刺性痤疮和炎症性痤疮以及色素沉着性皮肤疾病方面有效。本研究的目的是比较新开发的脂质体水凝胶(脂质体凝胶)和市售产品在活性物质壬二酸生物利用度方面的差异。对局部制剂进行了物理参数评估,如 pH 值测量、感官评价和脂质体大小分析。此外,还根据欧洲药典和国际协调会议制定的指南,对体外抗菌保存、稳定性和在角质层中的积累进行了研究。新的壬二酸脂质体凝胶配方具有药物制剂所需的稳定性。此外,所提出的 F2 配方显示出在角质层中非常高的活性物质积累(187.5μg/cm),这使得可以将 API 含量降低到 10%,与参考配方(市售的含有 20%壬二酸的乳膏)相比。研究表明,含有壬二酸的脂质体凝胶 F2 的最终配方具有可接受的物理参数,表明它们与皮肤相容,此外,该配方通过了稳定性研究。体外抗菌保存研究表明,所配制的脂质体凝胶 F2 具有很强的抗菌活性;因此,最终制剂中未添加防腐剂。本研究得出结论,含有壬二酸的脂质体凝胶 F2 稳定、抗菌保存效果好,并显示出改善的活性物质生物利用度。